Skip to main content

Table 1 Oncogenic viruses, associated malignancies and oncogenes

From: Designer nucleases to treat malignant cancers driven by viral oncogenes

Etiological agent

Malignancies and other disorders

Targeted and potential oncogenes

Review reference

HPV

Cervical cancer

Oropharyngeal cancer

Vagina cancer

Penile cancer

Anal cancer

Vulvar cancer

E6a

E7a

[12, 13]

HTLV-1

Adult T-cell leukemia/lymphoma (ATL)

HTLV-1 associated

myelopathy/tropical spastic paraparesis (HAM/TSP)

HBZ RNA

HBZ protein

[14]

EBV

(HHV-4)

Burkitt’s lymphoma (BL)

Hodgkin’s lymphoma (HL)

Diffuse large B cell lymphoma (DLBCL)

NK/T cell lymphoma

Post-transplant lymphoproliferative disorders (PTLD)

Nasopharyngeal carcinoma (NPC)

Gastric carcinoma (GC)

Latent coding

 EBNA1a

 EBNA2

 EBNA3A

 EBNA3C

 LMP1a

 LMP2Aa

Latent non-coding

 EBERs

 EBV miRNAsa

[15, 16]

KSHV

(HHV-8)

Kaposi's sarcoma (KS)

Primary effusion lymphoma (PEL)

Multicentric Castleman disease (MCD)

Latent coding

 LANAa

 Kaposin

 Viral cyclin (vCyclin)

 Viral FLIP (vFLIP)

Latent non-coding

 K12-miRNAsa

[17, 18]

MCPyV

Merkel cell carcinoma (MCC)

Large antigen (LT)a

Small antigen (sT)a

[19]

  1. Etiological agents with a list of their known associated cancers and other related disorders are shown. The genes that are the main oncogenic drivers of these cancers are highlighted as well as other potential targets for nuclease inactivation
  2. aStudies inactivating the oncogene with designer nucleases